Drug Resistant Pulmonary Tuberculosis Market

Drug Resistant Pulmonary Tuberculosis Market:Global Industry Analysis 2015 - 2019 and Opportunity Assessment 2020 - 2030

Market Overview

Tuberculosis is a leading cause of mortality and morbidity worldwide. Diagnosis, treatment, and prevention of TB has become more complex because of resistance to commonly used antituberculous drugs.

Drug resistant pulmonary tuberculosis refers to tuberculosis caused by an isolate of Mycobacterium tuberculosis that is resistant to one or more antituberculousis drugs. The drug resistant pulmonary tuberculosis market is expected to experience substantial growth during the forecast period due to rising incidence of the disease.

The market is segmented based on types, therapy types and distribution channel. Based on types, the market is segmented into mono drug resistant tuberculosis, multidrug resistant tuberculosis, extensive drug resistant tuberculosis and totally drug resistant tuberculosis.

Multidrug resistant tuberculosis is predicted to be the highest contributor in this segment due to its growing incidence.With the COVID-19 breakout in December 2019, the disease has affected more than 200 countries. 

Therefore, it is important to take this into consideration while addressing drug resistant pulmonary tuberculosis market. The disease may have led to temporary lag in the drug resistant pulmonary tuberculosis market, but in the long run the market is expected to pace up and flourish at a significant rate during the forecast period 2020-2030.

Drug Resistant Pulmonary Tuberculosis Market: Drivers and Restraints

The rising prevalence of multidrug resistant tuberculosis is expected to be the major factor to drive the growth of drug resistant pulmonary tuberculosis market. Increasing research and development in novel drug development is also expected to boost the global drug resistant pulmonary tuberculosis market.

Additionally, collaborations among international organizations, such as UNICEF, WHO, and TB alliance, focusing on development of treatment with shorter regimensin order to fight drug resistance is expected to address unmet medical needs, which will lead to significant market growth during the forecast period. 

However, some adverse drug reaction to the body may restrict the growth of drug resistant pulmonary tuberculosis market.

Drug Resistant Pulmonary Tuberculosis Market: Overview

Drug resistant pulmonary tuberculosis market is expected to experience steady growth during the forecast period due to increasing prevalence of the disease.

Based on disease type, the market is segmented into totally drug resistant tuberculosis, extensive drug resistant tuberculosis, multidrug resistant tuberculosis and mono drug resistant tuberculosis. The multidrug resistant tuberculosis is expected to grow substantially in this segment due to rising incidence of multidrug tuberculosis.

Based on therapy type, the global drug resistant pulmonary tuberculosis market is segmented into first line anti TB- drugs and second line anti TB-drugs. In this segment, the second line is expected to contribute major revenue as first line anti TB-drugs can be used only to treat mono drug resistant tuberculosis.

The first line anti TB- drugs is further segmented into isoniazid, ethambutol, pyrazinamide, rifambutin, streptomycin and others. Furthermore, the second line anti TB-drugs market is segmented into cycloserine, moxifloxacin, gatifloxacin, Amikacin, Ethionomide, capreomycin and others.

Based of distribution channel, the drug resistant pulmonary tuberculosis is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Retail pharmacy is expected to dominate the market during the forecast period.

Drug Resistant Pulmonary Tuberculosis Market: Regional-WiseOutlook

Geographically, the drug resistant pulmonary tuberculosis market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa.

South Asia and East Asia is expected to account for the largest share in the drug resistant pulmonary tuberculosis market due to high incidence of the disease, rising population awareness regarding hazards of medication compliance, and improving healthcare infrastructure.

China and India are expected to be the major contributors in this region. North America and Europe is expected to witness rapid growth during the forecast period. Although North America reports low drug resistant pulmonary tuberculosis incidence and prevalence, a higher immigrant population calls for greater focus on screening of the disease.

Developing medical infrastructure and increasing awareness may lead to steady growth in Latin America. In the Middle East and Africa the market growth is expected to grow significantly due to increasing prevalence and incidence in this region.

However, theslow economic growth, underdeveloped infrastructure and lower access to technological advancement may limit the growth of the market in this region.

Drug Resistant Pulmonary Tuberculosis Market: Key players

Some of the players identified in the drug resistant pulmonary tuberculosis marketinclude:

  • Bayer AG
  • Lupin Ltd.
  • Sandoz International GmbH
  • GlaxoSmithKline
  • Zydus Cadila
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astra Zeneca
  • Merck & Co.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology Matrix
  • Value Chain

Regional analysis of the drug resistant pulmonary tuberculosis market report includes

  • North America
  • Latin America
  • Europe
  • South  Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Drug resistant pulmonary tuberculosis market Report Highlights:

  • Overview of Global Healthcare Market
  • Evolution of the technology
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.

Drug Resistant Pulmonary Tuberculosis Market: Segmentation

Tentatively, the global drug resistant pulmonary tuberculosis market has been segmented on the basis of disease type, therapy type and distribution channel.

Disease type :

  • Totally drug resistant tuberculosis
  • Extensively drug resistant tuberculosis
  • Multidrug resistant tuberculosis
  • Mono drug resistant tuberculosis

Therapy type:

  • First line anti-TB drugs
  • Isoniazid
  • Ethambutol
  • Pyrazinamide
  • Rifabutin
  • Streptomycin
  • Others
  • Second line anti-TB drugs
  • Moxifloxacin
  • Gatifloxacin
  • Ethionomide
  • Capreomycin
  • Cycloserine
  • Others

Distribution channel? :

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

Region?:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Drug Resistant Pulmonary Tuberculosis Market